SCHEMBL10317964

SCHEMBL10317964

Cc1nnc(-c2ccc(Oc3cc(O[C@@H]4CCNC4=O)cc(C(=O)Nc4nc(-c5ccccc5)cs4)c3)cc2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ADORA3 P0DMS8 1/20 0.44
GCK P35557 5/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
LMNA P02545 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
PARP1 P09874 1/20 0.41
PKM P14618 1/20 0.41
ALOX12 P18054 1/20 0.41
HTT P42858 1/20 0.41
THRB P10828 1/20 0.40
KCNQ1 P51787 1/20 0.40
RAB9A P51151 1/20 0.40
CSNK2A2 P19784 1/20 0.40
CSNK2B P67870 1/20 0.40
CSNK2A1 P68400 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10318380 1.00 MAPT (0.46) MAPTKDM4EMEN1KMT2AADORA3
SCHEMBL10317965 1.00 MAPT (0.46) MAPTKDM4EMEN1KMT2AADORA3
SCHEMBL10318558 0.91 GCK (0.47) GCK
SCHEMBL10318557 0.91 GCK (0.47) GCK
SCHEMBL10320244 0.91 GCK (0.47) GCK
SCHEMBL1271044 0.90 GCK (0.41) GCK
SCHEMBL15252311 0.90 GCK (0.41) GCK
SCHEMBL15252276 0.90 GCK (0.41) GCK
SCHEMBL1272025 0.87 MAPT (0.46) MAPTKDM4EMEN1KMT2AADORA3
SCHEMBL10318093 0.86 NPC1 (0.42) MAPTKDM4EMEN1KMT2AGCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835469-B2 Substituted benzamide derivatives as glucokinase (GK) activators CADILA HEALTHCARE LIMITED (IN) 2014-09-16 US claimed
EP-2459554-B1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LTD (IN) 2013-09-18 EP claimed
US-20120184544-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2012-07-19 US claimed
US-8835469-B2 Substituted benzamide derivatives as glucokinase (GK) activators CADILA HEALTHCARE LIMITED (IN) 2014-09-16 US disclosed
EP-2459554-B1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LTD (IN) 2013-09-18 EP disclosed
US-20120184544-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184544-A1 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS GCKR, GCK, GK MAPT 3818/4885KDM4E 1736/4885MEN1 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.